Nanoplatform-based synergistic cancer Immuno-Chemodynamic therapy.

Int J Pharm

Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing, 314001, PR China. Electronic address:

Published: December 2024

Immunotherapy has made excellent breakthroughs in the field of cancer treatments, but faces challenges with low immunogenicity of tumor cells and an immunosuppressive tumor microenvironment (ITME). The emerging chemodynamic therapy (CDT) based on the Fenton/Fenton-like reaction can induce immunogenic cell death (ICD) to enhance tumor immunogenicity, facilitating the transition from immune-cold to immune-hot tumors. Synergistic CDT and immunotherapy based on advanced nanotechnology have shown immense promise for improving therapeutic efficacy while minimizing side effects in cancer treatment. This review summarizes and discusses recent advances in the field, with the goal of designing a high-quality nanoplatform to enhance synergistic CDT in combination with immunotherapy and lay the foundation for its future clinical translation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2024.124956DOI Listing

Publication Analysis

Top Keywords

synergistic cdt
8
nanoplatform-based synergistic
4
synergistic cancer
4
cancer immuno-chemodynamic
4
immuno-chemodynamic therapy
4
therapy immunotherapy
4
immunotherapy excellent
4
excellent breakthroughs
4
breakthroughs field
4
field cancer
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!